Cargando…

A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation

BACKGROUND: New-onset diabetes mellitus after transplantation (NODAT), a frequent and serious complication after transplantation, is associated with decreased graft and patient survival. Currently, it is diagnosed and treated primarily according to existing guidelines for type II diabetes. To date,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haidinger, Michael, Werzowa, Johannes, Voigt, Hans-Christian, Pleiner, Johannes, Stemer, Gunar, Hecking, Manfred, Döller, Dominik, Hörl, Walter H, Weichhart, Thomas, Säemann, Marcus D
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2984585/ https://www.ncbi.nlm.nih.gov/pubmed/20925938 http://dx.doi.org/10.1186/1745-6215-11-91

Ejemplares similares

Fluid overload in hemodialysis patients: a cross-sectional study to determine its association with cardiac biomarkers and nutritional status
por: Antlanger, Marlies, et al.
Publicado: (2013)

Glucose Metabolism After Renal Transplantation
por: Hecking, Manfred, et al.
Publicado: (2013)

Blood volume-monitored regulation of ultrafiltration in fluid-overloaded hemodialysis patients: study protocol for a randomized controlled trial
por: Hecking, Manfred, et al.
Publicado: (2012)

Cardiovascular events associate with diabetes status rather than with early basal insulin treatment for the prevention of post-transplantation diabetes mellitus
por: Topitz, David, et al.
Publicado: (2019)

Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety
por: Schwaiger, Elisabeth, et al.
Publicado: (2019)

A randomized controlled trial-based algorithm for insulin-pump therapy in hyperglycemic patients early after kidney transplantation
por: Werzowa, Johannes M., et al.
Publicado: (2018)

Comment on: Chakkera et al. Can New-Onset Diabetes After Kidney Transplant Be Prevented? Diabetes Care 2013;36:1406–1412
por: Hecking, Manfred, et al.
Publicado: (2013)

Combined sodium glucose co‐transporter‐2 inhibitor and angiotensin‐converting enzyme inhibition upregulates the renin‐angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double‐blind, placebo‐controlled exploratory trial
por: Antlanger, Marlies, et al.
Publicado: (2022)

Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management
por: Das, Sambit, et al.
Publicado: (2021)

Efficacy and Safety of a Single-Pill Combination of Vildagliptin and Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Odawara, Masato, et al.
Publicado: (2015)

The potential role of vildagliptin in the management and prevention of type 2 diabetes mellitus
por: Chakraborti, C.K.
Publicado: (2008)

Vildagliptin: a new oral treatment for type 2 diabetes mellitus
por: Mathieu, Chantal, et al.
Publicado: (2008)

Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
por: Profit, Louise, et al.
Publicado: (2008)

Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in “Real-World” Management of Type 2 Diabetes Mellitus: The G-FORCE Study
por: Van Gaal, Luc, et al.
Publicado: (2019)

Criteria for prediabetes and posttransplant diabetes mellitus after kidney transplantation: A 2‐year diagnostic accuracy study of participants from a randomized controlled trial
por: Kurnikowski, Amelie, et al.
Publicado: (2022)

Ten Years of Vildagliptin
por: Del Prato, Stefano
Publicado: (2017)

Surfing the Vildagliptin Tsunami
por: Balachandran, Karthik
Publicado: (2020)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2012)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2013)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over three months in patients with type 2 diabetes mellitus’
por: Mundra, Vishal
Publicado: (2012)

Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
por: Dejager, Sylvie, et al.
Publicado: (2012)

Effect of Vildagliptin on Hepatic Steatosis
por: Macauley, Mavin, et al.
Publicado: (2015)

Real-World Observational Study on Vildagliptin With Insulin (VIL-INS) or Vildagliptin and Metformin With Insulin (VIL-MET-INS) Therapy in Indian Patients With Type 2 Diabetes Mellitus
por: Panneerselvam, P, et al.
Publicado: (2023)

Bioimpedance Spectroscopy for Assessment of Volume Status in Patients before and after General Anaesthesia
por: Ernstbrunner, Matthäus, et al.
Publicado: (2014)

Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
por: Odawara, Masato, et al.
Publicado: (2014)

Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population
por: Khan, Asima, et al.
Publicado: (2022)

Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review
por: Sridhar, GR, et al.
Publicado: (2023)

Intrarenal Renin-Angiotensin-System Dysregulation after Kidney Transplantation
por: Kovarik, Johannes J., et al.
Publicado: (2019)

Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: a systematic literature review
por: Stemer , Gunar, et al.
Publicado: (2011)

Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation
por: Gueler, Ibrahim, et al.
Publicado: (2013)

Metformin and/or vildagliptin mitigate type II diabetes mellitus induced-oxidative stress: The intriguing effect
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2020)

Mild acute pancreatitis with vildagliptin use
por: Saraogi, Ravikant, et al.
Publicado: (2012)

Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
por: Wiciński, Michał, et al.
Publicado: (2020)

Intravenous Fluid Challenge Decreases Intracellular Volume: A Bioimpedance Spectroscopy-Based Crossover Study in Healthy Volunteers
por: Ernstbrunner, Matthäus, et al.
Publicado: (2017)

Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study
por: Hirose, Takahisa, et al.
Publicado: (2015)

Efficacy of vildagliptin for prevention of postpartum diabetes in women with a recent history of insulin-requiring gestational diabetes: A phase II, randomized, double-blind, placebo-controlled study
por: Hummel, Sandra, et al.
Publicado: (2018)

Effects of vildagliptin on wound healing and markers of inflammation in patients with type 2 diabetic foot ulcer: a prospective, randomized, double-blind, placebo-controlled, single-center study
por: Vangaveti, Venkat N., et al.
Publicado: (2022)

Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients
por: Cakirca, Mustafa, et al.
Publicado: (2014)

Conversion from Tacrolimus to Cyclosporine A Improves Glucose Tolerance in HCV-Positive Renal Transplant Recipients
por: Handisurya, Ammon, et al.
Publicado: (2016)

Evaluation of risk factor management of patients treated on an internal nephrology ward: a pilot study
por: Stemer, Gunar, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_19b5nb6cklghtup029hamfia3t